Keros Therapeutics to receive $20 million milestone payment following Phase 3 trial progress

Filing content

Keros Therapeutics expects to receive a $20 million milestone payment from Takeda following the first patient dosing in the ELRiSE MF Phase 3 trial. The company plans to distribute 25% of the net proceeds to stockholders.